224 related articles for article (PubMed ID: 21757445)
1. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.
Badr CE; Wurdinger T; Nilsson J; Niers JM; Whalen M; Degterev A; Tannous BA
Neuro Oncol; 2011 Nov; 13(11):1213-24. PubMed ID: 21757445
[TBL] [Abstract][Full Text] [Related]
2. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
Crommentuijn MH; Maguire CA; Niers JM; Vandertop WP; Badr CE; Würdinger T; Tannous BA
Mol Oncol; 2016 Apr; 10(4):625-34. PubMed ID: 26708508
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation).
Zhou X; Lv L; Tan Y; Zhang Z; Wei S; Xiao S
Brain Res; 2021 Sep; 1766():147515. PubMed ID: 33984327
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
Murphy ÁC; Weyhenmeyer B; Noonan J; Kilbride SM; Schimansky S; Loh KP; Kögel D; Letai AG; Prehn JH; Murphy BM
Apoptosis; 2014 Apr; 19(4):629-42. PubMed ID: 24213561
[TBL] [Abstract][Full Text] [Related]
5. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
Bagci-Onder T; Agarwal A; Flusberg D; Wanningen S; Sorger P; Shah K
Oncogene; 2013 Jun; 32(23):2818-27. PubMed ID: 22824792
[TBL] [Abstract][Full Text] [Related]
6. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953
[TBL] [Abstract][Full Text] [Related]
7. Overcoming TRAIL Resistance for Glioblastoma Treatment.
Deng L; Zhai X; Liang P; Cui H
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33919846
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
[TBL] [Abstract][Full Text] [Related]
9. Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells.
Zhu ZC; Liu JW; Yang C; Li MJ; Wu RJ; Xiong ZQ
Cell Death Dis; 2019 Feb; 10(2):118. PubMed ID: 30742128
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.
Dorsey JF; Mintz A; Tian X; Dowling ML; Plastaras JP; Dicker DT; Kao GD; El-Deiry WS
Mol Cancer Ther; 2009 Dec; 8(12):3285-95. PubMed ID: 19996278
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.
Liu PC; Lu G; Deng Y; Wang CD; Su XW; Zhou JY; Chan TM; Hu X; Poon WS
PLoS One; 2017; 12(1):e0171157. PubMed ID: 28135339
[TBL] [Abstract][Full Text] [Related]
12. The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma.
Ozyerli-Goknar E; Sur-Erdem I; Seker F; Cingöz A; Kayabolen A; Kahya-Yesil Z; Uyulur F; Gezen M; Tolay N; Erman B; Gönen M; Dunford J; Oppermann U; Bagci-Onder T
Cell Death Dis; 2019 Nov; 10(12):894. PubMed ID: 31772153
[TBL] [Abstract][Full Text] [Related]
13. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
Bhere D; Tamura K; Wakimoto H; Choi SH; Purow B; Debatisse J; Shah K
Neuro Oncol; 2018 Jan; 20(2):215-224. PubMed ID: 29016934
[TBL] [Abstract][Full Text] [Related]
14. Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin.
Lee DH; Lee CS; Kim DW; Ae JE; Lee TH
Anticancer Drugs; 2014 Jan; 25(1):44-52. PubMed ID: 24045365
[TBL] [Abstract][Full Text] [Related]
15. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
16. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255
[TBL] [Abstract][Full Text] [Related]
17. BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas.
Burton TR; Henson ES; Azad MB; Brown M; Eisenstat DD; Gibson SB
Cell Death Dis; 2013 Apr; 4(4):e587. PubMed ID: 23579274
[TBL] [Abstract][Full Text] [Related]
18. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.
Park KJ; Lee SH; Kim TI; Lee HW; Lee CH; Kim EH; Jang JY; Choi KS; Kwon MH; Kim YS
Cancer Res; 2007 Aug; 67(15):7327-34. PubMed ID: 17671202
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
[TBL] [Abstract][Full Text] [Related]
20. Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.
Khan M; Bi Y; Qazi JI; Fan L; Gao H
Mol Med Rep; 2015 Jan; 11(1):257-62. PubMed ID: 25333675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
